Quantitative Measurements of LRRK2 in Human Cerebrospinal Fluid Demonstrates Increased Levels in G2019S Patients

New article: Quantitative Measurements of LRRK2 in Human Cerebrospinal Fluid Demonstrates Increased Levels in G2019S Patients. https://t.co/27e7MSZah4 #parkinsons #neurology https://t.co/3xFxALAKp4

#Parkinsons #biomarkers are crucial for clinical trials. @biogen team now improved #LRRK2 detection in cerebrospinal fluid using an antibody peptide capture technique combined with #MassSpec (1ml, 105/106 patients positiv, highest when G2019S LRRK2 & &

Interesting - @biogen researchers report quantitative measurements of #Parkinsons-associated LRRK2 in human cerebrospinal fluid, & demonstrate increased levels in G2019S carriers (106 CSF samples from the @MichaelJFoxOrg LRRK2 Cohort Consortium) https:

New Research: Quantitative Measurements of LRRK2 in Human Cerebrospinal Fluid Demonstrates Increased Levels in G2019S Patients: Leucine-rich repeat kinase 2 (LRRK2) mutations are among the most significant genetic risk factors for… https://t.co/yAkgFbfifU